H.C. Wainwright analyst Arthur He initiated coverage of Adagene with a Buy rating and $5 price target. Adagene is a clinical-stage biopharmaceutical company focused on developing nextgeneration antibody therapies to treat cancers based on its proprietary platforms, including NEObody, SAFEbody, and POWERbody, He tells investors in a research note. The analyst says the company has established a "deep and diversified pipeline" with two prioritized clinical-stage programs.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ADAG:
- Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
- Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November